Detalhe da pesquisa
1.
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
Clin Infect Dis
; 71(10): e594-e603, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32201897
2.
Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
J Infect Dis
; 218(5): 748-756, 2018 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29684148
3.
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Clin Infect Dis
; 59(3): 425-34, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24729492
4.
Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Int J Clin Pharmacol Ther
; 52(2): 118-28, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24161160
5.
Assessment of Illness Severity in Adults Hospitalized With Acute Respiratory Tract Infection due to Influenza, Respiratory Syncytial Virus, or Human Metapneumovirus.
Influenza Other Respir Viruses
; 18(5): e13275, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692663
6.
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Paediatr Drugs
; 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649595
7.
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Clin Microbiol Infect
; 29(10): 1320-1327, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37422079
8.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
J Antimicrob Chemother
; 67(8): 2020-8, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22532465
9.
Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation.
Patient Relat Outcome Meas
; 12: 247-265, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34326675
10.
Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor.
Adv Ther
; 37(1): 578-591, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31832988
11.
Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Clin Pharmacokinet
; 56(11): 1331-1342, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238203
12.
Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics.
Pediatr Infect Dis J
; 35(11): 1215-1221, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27294305
13.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Lancet Infect Dis
; 15(10): 1145-1155, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26201299
14.
The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
J Clin Pharmacol
; 54(2): 133-40, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24203510
15.
Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
J Acquir Immune Defic Syndr
; 67(5): 487-92, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25473882
16.
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
J Clin Pharmacol
; 54(5): 563-73, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25975423
17.
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
AIDS Patient Care STDS
; 28(4): 168-75, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24660840
18.
96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Antivir Ther
; 18(8): 967-77, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23714781
19.
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
AIDS
; 27(6): 889-897, 2013 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-23276806
20.
Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
AIDS Rev
; 15(2): 87-101, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23681436